MAP2K7 and malignant peripheral nerve sheath tumor: Clinical efficacy of MEK inhibitor monotherapy in MPNST has not been reported to date, but a Phase 2 trial is testing the combination of selumetinib and sirolimus (mTOR inhibitor) in MPNST (NCT03433183).